Clinical trials
Phase 3 Overweight trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
111 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 3 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 10 |
| 2024 | 4 |
| 2025 | 20 |
| 2026 | 40 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
| Recruiting | 40 |
| Active, not recruiting | 21 |
| Not yet recruiting | 4 |
| Terminated | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 36 |
| Novo Nordisk A/S | 23 |
| Amgen | 8 |
| Orexigen Therapeutics, Inc | 6 |
| Hoffmann-La Roche | 5 |
| Pfizer | 5 |
| AstraZeneca | 4 |
| Ascletis Pharma (China) Co., Limited | 2 |
| Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2 |
| Kailera | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Overweight | 111 |
| Obesity | 107 |
| Diabetes Mellitus, Type 2 | 24 |
| Nutrition Disorders | 9 |
| Diabetes Mellitus | 6 |
| Sleep Apnea, Obstructive | 6 |
| Body Weight | 5 |
| Weight Loss | 5 |
| Prediabetic State | 4 |
| Cardiovascular Diseases | 3 |
Trials
Showing 1 to 25 of 111. Each trial links to its page on Pharma Observatory.
11 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.